This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Lipids and Lipid Disorders  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Humanities  • Medicine and the Media  • Alert me on articles by topic  Social Bookmarking   What's this?

Philip Greenland, MD; Donald Lloyd-Jones, MD, ScM

JAMA. 2008;299(8):953-955.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The unusual release on January 14, 2008, in the news media and on a drug company Web site,¹ of a portion of the Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) trial data resulted in numerous articles and commentaries in the lay media. The availability of only fragmentary information created massive confusion and raised many more questions than answers for patients, physicians, pharmaceutical companies, and regulators. A full report of the ENHANCE trial in a peer-reviewed medical journal is not expected for months, and the first public presentation of the study's findings in a medical setting will not occur before late March 2008.

The purpose of this Commentary is to review key features of the ENHANCE study and to point to lessons that should be learned by drug companies, clinical researchers, clinicians, and health agencies from . . . [Full Text of this Article]

Background on the ENHANCE Trial

Lesson 1: Drug Trials Should Not Be Done for Marketing Purposes Only

Lesson 2: The News Media Must Be Sure to Get the Facts Straight. Errors in Reporting Can Cause Serious Damage, and Patients May Be Harmed or Become Distressed From the Resulting Confusion

Lesson 3: Leading Scientific, Patient-Oriented, and Disease-Oriented Organizations Must Scrupulously Avoid Conflict of Interest

Author Affiliations: Departments of Preventive Medicine and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Dr Greenland is Editor, Archives of Internal Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

The ENHANCE Study and Marketing Ezetimibe
Fatima Akdim, John J. P. Kastelein, and Daniel Gaudet
JAMA. 2008;299(23):2747.
EXTRACT | FULL TEXT  

The ENHANCE Study and Marketing Ezetimibe—Reply
Philip Greenland and Donald Lloyd-Jones
JAMA. 2008;299(23):2747-2748.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Controversies Surround Heart Drug Study: Questions About Vytorin and Trial Sponsors' Conduct
Mike Mitka
JAMA. 2008;299(8):885-887.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals
Mello et al.
NEJM 2009;360:1557-1566.
FULL TEXT  

The ADVANTAGE Seeding Trial: A Review of Internal Documents
Hill et al.
ANN INTERN MED 2008;149:251-258.
ABSTRACT | FULL TEXT  

The ENHANCE Study and Marketing Ezetimibe
Akdim et al.
JAMA 2008;299:2747-2747.
FULL TEXT  

Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs
Psaty and Lumley
JAMA 2008;299:1474-1476.
FULL TEXT